{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:42:31Z","timestamp":1778791351698,"version":"3.51.4"},"reference-count":69,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T00:00:00Z","timestamp":1657411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Breast cancer is the most commonly diagnosed cancer worldwide and the fifth leading cause of cancer death. In 2020, there were 2.3 million new cases, and 685,000 women died from it. Breast cancer among young women under 40 years of age accounts for 5% to 10% of all cases of this cancer. The greater availability of multi-gene sequence analysis by next-generation sequencing has improved diagnosis and, consequently, the possibility of using appropriate therapeutic approaches in BRCA1\/2 gene mutation carriers. Treatment of young breast cancer patients affects their reproductive potential by reducing ovarian reserve. It can lead to reversible or permanent premature menopause, decreased libido, and other symptoms of sex hormone deficiency. This requires that, in addition to oncological treatment, patients are offered genetic counseling, oncofertility, psychological assistance, and sexological counseling. Given the number of BRCA1\/2 gene mutation carriers among young breast cancer patients, but also thanks to growing public awareness, among their healthy family members planning offspring, the possibility of benefiting from preimplantation testing and performing cancer-risk-reduction procedures: RRM (risk-reducing mastectomy) and RRSO (risk-reducing salpingo-oophorectomy) significantly increase the chance of a genetically burdened person living a healthy life and giving birth to a child not burdened by the parent\u2019s germline mutation. The goal of this paper is to show methods and examples of fertility counselling for BRCA1\/2 gene mutation carriers, including both patients already affected by cancer and healthy individuals.<\/jats:p>","DOI":"10.3390\/jcm11143996","type":"journal-article","created":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T22:48:00Z","timestamp":1657493280000},"page":"3996","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fertility Counseling in BRCA1\/2-Mutated Women with Breast Cancer and Healthy Individuals"],"prefix":"10.3390","volume":"11","author":[{"given":"Joanna","family":"Kufel-Grabowska","sequence":"first","affiliation":[{"name":"Department of Oncology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-5522","authenticated-orcid":false,"given":"Amira","family":"Podolak","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecological Nursing, Faculty of Health Sciences, Medical University of Gdansk, 80-210 Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Maliszewski","sequence":"additional","affiliation":[{"name":"Department of General and Oncological Surgery, Wojew\u00f3dzki Szpital Specjalistyczny im. Janusza Korczaka w S\u0142upsku Sp. z o.o., 76-200 S\u0142upsk, Poland"},{"name":"Department of General and Oncological Surgery at Specialist Hospital in Koscierzyn, Sp.z.o.o., 83-400 Ko\u015bcierzyna, Poland"},{"name":"Swissmed Health Center, 80-210 Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8728-5998","authenticated-orcid":false,"given":"Miko\u0142aj","family":"Bartoszkiewicz","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Poznan University of Medical Sciences, 60-806 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodryg","family":"Ramlau","sequence":"additional","affiliation":[{"name":"Department of Oncology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-6991","authenticated-orcid":false,"given":"Krzysztof","family":"Lukaszuk","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecological Nursing, Faculty of Health Sciences, Medical University of Gdansk, 80-210 Gdansk, Poland"},{"name":"Invicta Research and Development Center, 81-740 Sopot, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11864-019-0685-7","article-title":"Diagnosis and Treatment of Breast Cancer in Young Women","volume":"20","author":"Rossi","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-016-3983-9","article-title":"Long-term outcome in young women with breast cancer: A population-based study","volume":"160","author":"Fredholm","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P","article-title":"Frequency of BRCA1\/BRCA2 mutations in a population-based sample of young breast carcinoma cases","volume":"88","author":"Malone","year":"2000","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejogrb.2018.05.018","article-title":"Breast cancer screening in young women","volume":"230","author":"Desreux","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_6","unstructured":"(2022, March 21). Cancer Facts and Figures 2020. The National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results (SEER) Program. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2020.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: Different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12575-020-00133-5","article-title":"Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: Review of radiosensitivity assays","volume":"22","author":"Sadeghi","year":"2020","journal-title":"Biol. Proced. Online"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","article-title":"Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer","volume":"2","author":"Chen","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers","volume":"93","author":"Hartmann","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Seynaeve","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10549-009-0497-8","article-title":"Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)","volume":"120","author":"Kiely","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: Retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.09.005","article-title":"Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know","volume":"61","author":"Marchetti","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_22","first-page":"CD012464","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer","volume":"339","author":"Narod","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: A meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humupd\/dmq022","article-title":"Hormonal contraception and risk of cancer","volume":"16","author":"Cibula","year":"2010","journal-title":"Hum. Reprod. Update"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: A meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.fertnstert.2015.02.011","article-title":"Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers","volume":"103","author":"Perri","year":"2015","journal-title":"Fertil. Steril."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102110","DOI":"10.18632\/oncotarget.22193","article-title":"Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1158\/1055-9965.EPI-09-0024","article-title":"Oral contraceptive use and BRCA penetrance: A case-only study","volume":"18","author":"Pasanisi","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-013-2823-4","article-title":"Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers","volume":"143","author":"Kotsopoulos","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/annonc\/mdx639","article-title":"Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients","volume":"29","author":"Lambertini","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"ESHRE Guideline Group on Female Fertility Preservation, Anderson, R.A., Amant, F., Braat, D., D\u2019Angelo, A., Chuva de Sousa Lopes, S.M., Demeestere, I., Dwek, S., Frith, L., and Lambertini, M. (2020). ESHRE guideline: Female fertility preservation. Hum. Reprod. Open., 2020, hoaa052.","DOI":"10.1093\/hropen\/hoaa052"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-014-2914-x","article-title":"What lies behind chemotherapy-induced amenorrhea for breast cancer patients: A meta-analysis","volume":"145","author":"Zhao","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1200\/JCO.2006.06.5888","article-title":"American Society of Clinical Oncology recommendations on fertility preservation in cancer patients","volume":"24","author":"Lee","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","article-title":"Prospective evaluation of serum anti-M\u00fcllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer","volume":"79","author":"Dezellus","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.07.001","article-title":"Fertility and pregnancy issues in BRCA-mutated breast cancer patients","volume":"59","author":"Lambertini","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/humrep\/deg110","article-title":"Taskforce 5: Preimplantation genetic diagnosis","volume":"18","author":"Shenfield","year":"2003","journal-title":"Hum. Reprod."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/pd.1925","article-title":"Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth","volume":"28","author":"Jasper","year":"2008","journal-title":"Prenat. Diagn."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10549-014-2951-5","article-title":"Hereditary breast and ovarian cancer and reproduction: An observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors","volume":"145","author":"Mackens","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1093\/humrep\/dey321","article-title":"Elective and Onco-fertility preservation: Factors related to IVF outcomes","volume":"33","author":"Cobo","year":"2018","journal-title":"Hum. Reprod."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1210\/jc.2006-0962","article-title":"Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy","volume":"91","author":"Oktay","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jama.2016.9389","article-title":"Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer","volume":"316","author":"Spaan","year":"2016","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.fertnstert.2012.01.093","article-title":"Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment","volume":"97","author":"Domingo","year":"2012","journal-title":"Fertil. Steril."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10815-018-1227-0","article-title":"Fertility preservation: Ovarian response to freeze oocytes is not affected by different malignant diseases-an analysis of 992 stimulations","volume":"35","author":"Bruckner","year":"2018","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mds250","article-title":"Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: Menstruation and pregnancy outcomes","volume":"24","author":"Wong","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10815-018-1144-2","article-title":"Transplantation of frozen-thawed ovarian tissue: An update on worldwide activity published in peer-reviewed papers and on the Danish cohort","volume":"35","author":"Gellert","year":"2018","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.21.00535","article-title":"Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis","volume":"39","author":"Lambertini","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.rbmo.2013.09.017","article-title":"Probability of live birth in women with extremely low anti-M\u00fcllerian hormone concentrations","volume":"28","author":"Kunicki","year":"2014","journal-title":"Reprod. Biomed. Online"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/humrep\/del007","article-title":"Spontaneous conceptions and live birth after heterotopic ovarian transplantation: Is there a germline stem cell connection?","volume":"21","author":"Oktay","year":"2006","journal-title":"Hum. Reprod."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bpobgyn.2009.09.002","article-title":"Orthotopic and heterotopic ovarian tissue transplantation","volume":"24","author":"Sonmezer","year":"2010","journal-title":"Best Pr. Res. Clin. Obs. Gynaecol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1179558119828393","DOI":"10.1177\/1179558119828393","article-title":"Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?","volume":"13","author":"Lambertini","year":"2019","journal-title":"Clin. Med. Insights Reprod. Health"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12958-021-00827-9","article-title":"Preimplantation genetic testing for BRCA gene mutation carriers: A cost effectiveness analysis","volume":"19","author":"Michaan","year":"2021","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4103\/jhrs.JHRS_132_18","article-title":"Preimplantation Genetic Testing: Its Evolution, Where Are We Today?","volume":"11","author":"Parikh","year":"2018","journal-title":"J. Hum. Reprod. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3389\/fendo.2019.00845","article-title":"Utility and First Clinical Application of Screening Embryos for Polygenic Disease Risk Reduction","volume":"10","author":"Treff","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/ijc.26045","article-title":"Pregnancy after adolescent and adult cancer: A population-based matched cohort study","volume":"129","author":"Stensheim","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.19.02399","article-title":"Pregnancy After Breast Cancer in Patients with GermlineBRCAMutations","volume":"38","author":"Lambertini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.20.02253","article-title":"In Response to \u201cPregnancy After Breast Cancer in Patients with Germline BRCA Mutations\u201d","volume":"38","author":"Narod","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JCO.2012.44.2285","article-title":"Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: A multicenter retrospective study","volume":"31","author":"Azim","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/jnci\/djx206","article-title":"Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status","volume":"110","author":"Lambertini","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"djv202","DOI":"10.1093\/jnci\/djv202","article-title":"Impact of Fertility Concerns on Tamoxifen Initiation and Persistence","volume":"107","author":"Llarena","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.breast.2021.07.021","article-title":"Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy","volume":"59","author":"Partridge","year":"2021","journal-title":"Breast"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/3996\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:47:40Z","timestamp":1760140060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/3996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,10]]},"references-count":69,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcm11143996"],"URL":"https:\/\/doi.org\/10.3390\/jcm11143996","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,10]]}}}